Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes

Japanese Journal of Clinical Oncology

Volumn 36, Issue 8, 2006, Pages 523-526

  Chou, Wen Chi ^a   Huang, Shiu Feng ^b   Yeh, Kun Yang ^c   Wang, Hung Ming ^a   Liu, Mei Ying ^a   Hsieh, Jia Juan ^a   Cheung, Yun Chung ^a   Chang, John Wen Cheng ^a,d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c Pahai Hospital   (Taiwan)

^d NONE   (Taiwan)

Author keywords

Gene profiling, translational oncology; Lung cancer (diagnosis and; Signal transduction, EGFR mutation); Staging, translational oncology

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; NAVELBINE;

ADULT; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LAMINECTOMY; LOW BACK PAIN; LUNG ADENOCARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PERCUTANEOUS VERTEBROPLASTY; PROTEIN EXPRESSION; RADIATION DERMATITIS; SPINAL CORD METASTASIS; THORAX RADIOGRAPHY; TUMOR CELL; WEIGHT REDUCTION; WILD TYPE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENES, ERBB-1; HUMANS; LAMINECTOMY; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SPINAL NEOPLASMS;

EID: 33750109222     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl057     Document Type: Article

References (24)

1. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-67.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science (Wash DC) 304:1497-500, 2004.
4. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, et al. High Frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10:8195-203.
5. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-86.
6. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in nonsmall-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005:23:2493-501.
7. Raffaella Sordella, Daphne W, Bell, Daniel A. Haber, Jeffrey Settleman. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.
8. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
9. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;90:2149-58.
10. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, et al. Finals results of a Phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy (abstract P-611). Lung Cancer, 2003;41(Suppl. 2): S246.
11. Shepherd F, Pereira J, Ciuleanu E, Tan EH, Hirsh V, Thongprasert S, et al. A randomized placebo-controlled trial of erlotinib in patient with advanced non-small cell lung cancer following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc ASCO, 2004 (abstract number 7022).
12. Shepherd FA. Second-line chemotherapy for non-small cell lung cancer. Expert Rev Anticancer Ther 2003;3:435-42.
13. Giaccone G, Herbst RS, Maneglod C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall-cell lung cancer. A phase III trial -INTACT 1. J Clin Oncol 2004;22:777-84.
14. Herbst ER, Giaccone G, Schiller JH, Natale RB, Miller V, Mangold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer. A phase III trial -INTACT 2. J Clin Oncol 2004;22:785-94.
15. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Brennscheidt U, et al. Results of a phase III trial of Erlotinib combined with cisplatin and gemcitabine chemotherapy in advanced non-small cell lung cancer. Proc ASCO, 2004 (abstract number 7010).
16. Herbst RS, Prager D, Hermann R, Miller V, Fehrenbacher L, Hoffmann P, et al. A phase III trial of erlotinib combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. Proc ASCO, 2004 (abstract number 7011).
17. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-9.
18. Janne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004;44:221-30.
19. Bailey R, Kris M, Wolf M, Kay A, Averbuch S, Askaa J, et al. Gefitinib ('Iressa',ZD1839) monotherapy for pretreated advanced non-small cell lung cancer in IDEAL 1 and 2: Tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone. Lung Cancer 2003;41(Suppl. 2): S71.
20. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109:275.
21. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol Chem 2002;277:46265.
22. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in Cancer. J Clin Oncol 2005;23:2445-59.
23. Pao W, Miller VA, Politil KA, Riely GJ, Somwarl R, Zakowski MF, et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. PLoS Medicine 2005;2:e73.
24. Susumu,K, Titus BJ, Tajhal D, Pasi AJ, Olivier K, Matthew M, et al. Brief Report: EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib. NEJM 2005;352:786-92.